|
51 |
A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells
Enthalten in BMC cancer Bd. 13, 4.12.2013, Nr. 1, date:12.2013: 1-18
|
|
|
|
52 |
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Enthalten in Genome medicine Bd. 14, 15.9.2022, Nr. 1, date:12.2022: 1-19
|
|
|
|
53 |
Age-, tumor-, and metastatic tissue-associated DNA hypermethylation of a T-box brain 1 locus in human kidney tissue
Enthalten in Clinical epigenetics Bd. 12, 18.2.2020, Nr. 1, date:12.2020: 1-11
|
|
|
|
54 |
Alterations of neuropeptides in the human gut during peritonitis
Enthalten in Langenbeck's archives of surgery Bd. 392, 22.3.2007, Nr. 3, date:5.2007: 267-271
|
|
|
|
55 |
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?
Enthalten in World journal of urology Bd. 31, 11.3.2012, Nr. 2, date:4.2013: 345-350
|
|
|
|
56 |
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma
Enthalten in World journal of urology Bd. 42, 20.1.2024, Nr. 1, date:12.2024: 1-10
|
|
|
|
57 |
Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation
Enthalten in Journal of cancer research and clinical oncology Bd. 145, 22.4.2019, Nr. 7, date:7.2019: 1835-1843
|
|
|
|
58 |
Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)
Enthalten in Advances in therapy Bd. 35, 19.9.2018, Nr. 11, date:11.2018: 2054-2068
|
|
|
|
59 |
Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study
Enthalten in BMC cancer Bd. 14, 20.11.2014, Nr. 1, date:12.2014: 1-10
|
|
|
|
60 |
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
Enthalten in BMC medicine Bd. 16, 5.7.2018, Nr. 1, date:12.2018: 1-10
|
|
Administration
